Pacira BioSciences Q2 Earnings: Can EPS Recover After Q1 Miss?

Forward-Looking Analysis

Pacira BioSciences (PCRX) is scheduled to release its Q2 2026 earnings on August 4, 2026. Analyst consensus estimates, based on data from April 30, 2026, project an EPS of $0.61, though recent quarterly tables indicate a lower consensus average of $0.48 with a range between $0.27 and $0.69 across two analysts. Revenue estimates for the current fiscal year stand at a consensus of $761.5 million, while the company provided guidance of $745.0 million to $770.0 million following its Q1 report. Despite a slight miss in Q1, where EPS was $0.60 versus a $0.61 estimate, actual revenue of $177.38 million exceeded the $171.80 million consensus, demonstrating top-line resilience.

Forward-looking metrics suggest significant growth potential, with earnings expected to grow 39.79% next year from $1.91 to $2.67 per share. Long-term forecasts from eight analysts predict EPS will reach $2.93 in 2026, rising to $3.72 in 2027 and $4.63 by 2028, representing a three-year forecast increase of over 3,700%. Revenue is similarly projected to grow, reaching $781.7 million in one year and $949.7 million in three years. Wall Street sentiment remains cautiously optimistic, with a consensus "Buy" rating from four analysts and an average 12-month price target of $29.75, implying 17.45% upside from current levels. The highest price target stands at $38.00, while the lowest is $24.00. Although the trailing P/E ratio is elevated at 191.60, the forward P/E is significantly lower at 12.04, reflecting expectations for improved profitability. Analyst revisions have been mixed, with a neutral estimate revisions score, yet the broad consensus anticipates substantial earnings expansion over the next three years.

Historical Performance Review

Pacira BioSciences reported Q1 2026 results on April 30, 2026, delivering revenue of $177.38 million, which marked a 5.0% year-over-year increase and surpassed analyst estimates of $171.80 million. While the company reported an EPS of $0.07, this slightly missed the consensus estimate of $0.61 by $0.01. The quarter generated a net income of $2.92 million and achieved a gross profit of $140.96 million. This performance followed a Q4 2025 result where EPS missed estimates by $0.28, indicating a period of volatility in bottom-line profitability despite consistent top-line growth.

Additional News

Pacira BioSciences updated its full-year 2026 financial guidance on April 30, 2026, setting a revenue target between $745.0 million and $770.0 million. This guidance range aligns closely with the Wall Street consensus revenue estimate of $761.5 million for the fiscal year. The company has maintained a steady reporting schedule, with its Q1 2026 earnings released on April 30 and its Q2 2026 report anticipated for August 4. Analyst coverage remains active, with four providers offering 12-month price targets. The consensus recommendation among these analysts is a "Buy," with two analysts assigning a "Buy" rating and two assigning a "Hold." No significant mergers, acquisitions, or new product launches were detailed in the provided reports; the primary focus remains on the company's ability to meet its updated revenue guidance and improve earnings per share following the Q1 miss.

Summary & Outlook

Pacira BioSciences demonstrates solid top-line growth with a 5.0% revenue increase in Q1, though bottom-line profitability remains under pressure, evidenced by the Q1 EPS miss. The financial health is supported by strong gross margins and a clear path to expanded earnings, with analysts forecasting a 39.79% earnings growth rate next year. The primary catalyst is the anticipated improvement in net income and EPS, driven by operational efficiencies and revenue expansion. However, the high trailing P/E ratio introduces valuation risk. Given the consensus "Buy" rating, rising revenue projections, and significant long-term EPS growth forecasts, the outlook is cautiously bullish, contingent on the company meeting its updated FY2026 revenue guidance and reversing the recent earnings miss trend in Q2.